Rigel Deferred Long Term Liab from 2010 to 2024
| RIGL Stock | USD 26.70 0.61 2.34% |
Deferred Long Term Liabilities | First Reported 2011-06-30 | Previous Quarter 0.0 | Current Value 90 K | Quarterly Volatility 4.7 M |
Check Rigel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rigel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 7.2 M or Total Revenue of 122.7 M, as well as many indicators such as Price To Sales Ratio of 2.05, Dividend Yield of 0.0 or Days Sales Outstanding of 63.95. Rigel financial statements analysis is a perfect complement when working with Rigel Pharmaceuticals Valuation or Volatility modules.
Rigel | Deferred Long Term Liab |
Latest Rigel Pharmaceuticals' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Rigel Pharmaceuticals over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Rigel Pharmaceuticals' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rigel Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Rigel Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 3,618,863 | |
| Geometric Mean | 618,333 | |
| Coefficient Of Variation | 125.73 | |
| Mean Deviation | 4,180,643 | |
| Median | 90,000 | |
| Standard Deviation | 4,549,858 | |
| Sample Variance | 20.7T | |
| Range | 11.7M | |
| R-Value | (0.85) | |
| Mean Square Error | 6.4T | |
| R-Squared | 0.71 | |
| Significance | 0.000073 | |
| Slope | (859,741) | |
| Total Sum of Squares | 289.8T |
Rigel Deferred Long Term Liab History
About Rigel Pharmaceuticals Financial Statements
Rigel Pharmaceuticals investors utilize fundamental indicators, such as Deferred Long Term Liab, to predict how Rigel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 81 K | 77 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Rigel Pharmaceuticals Correlation against competitors. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.27 | Revenue Per Share 8.979 | Quarterly Revenue Growth 0.966 | Return On Assets 0.0461 |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.